Survodutide alternatives.
10 compounds compared to Survodutide, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Almost nobody searching for survodutide alternatives has a problem with survodutide. The problem is access. It is investigational, has not been approved by the FDA, EMA, or any major regulator, and legitimate use means enrolling in a registered trial you may not qualify for or live near. So the real question is which dual or single incretin agonist you can actually be prescribed today. That points toward semaglutide and tirzepatide, both of which completed registrational programs and hold approvals, rather than toward the other investigational dual agonists that sit in the same waiting room. Its Breakthrough Therapy designation for MASH with fibrosis is a review-speed designation, not availability.
Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R).
- 01MazdutideB tierIn human trialsIBI362 · LY3305677
Acts through the glp-1 receptor agonism pathway, like Survodutide. In human trials.
- 02RetatrutideB tierIn human trialstriple agonist
Acts through the glp-1 receptor agonism pathway, like Survodutide. In human trials.
- 03SemaglutideS tierFDA-approvedOzempic · Wegovy
Acts through the glp-1 receptor agonism pathway, like Survodutide. FDA-approved.
- 04LiraglutideS tierFDA-approvedVictoza · Saxenda
Acts through the glp-1 receptor agonism pathway, like Survodutide. FDA-approved.
- 05TirzepatideS tierFDA-approvedMounjaro · Zepbound
Acts through the glp-1 receptor agonism pathway, like Survodutide. FDA-approved.
- 06CagriSemaC tierIn human trialscagrilintide + semaglutide
Acts through the glp-1 receptor agonism pathway, like Survodutide. In human trials.
- 07
- 08AOD-9604D tierResearch / preclinical
Same category: metabolic & glp-1. Research / preclinical.
- 09HGH Fragment 176-191F tierResearch / preclinicalhGH frag 176-191 · GH lipolytic fragment
Same category: metabolic & glp-1. Research / preclinical.
- 10
An “alternative” here means a compound that shares Survodutide's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.